Inve India ▾

Alembic Pharmaceuticals share price & results

Alembic Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Vadodara-based integrated pharma maker of branded generics, US/global formulations and APIs across 10 plants.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,868 ₹ crore+25.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin19.0 %+5.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit197 ₹ crore+89.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity13.73 %+2.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.95 %+10.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)14.10 %+3.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 7 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Alembic Pharmaceuticals Limited management guidance track record on Inve: 19 targets tracked across analysed earnings calls (3 achieved, 4 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Borrowing Levelhopefully, the borrowing level will be much lower by -- before end of the year
Call transcript, Q2 FY25 · 7 Nov 2024		Q2 FY25Q1 FY27:Gross debt increased to ₹1,600 crores. Management plans to reduce it in subsequent quarters, but the level continues to deviate from the original goal.
Call transcript, Q1 FY27 · 4 Aug 2026		Missed
EBITDA Margin Target18%-19%-20% kind of EBITDA levels... over the next couple of years
Call transcript, Q4 FY25 · 6 May 2025		Q4 FY25Q1 FY27:Q1 FY27 reported EBITDA margin was 16%, moving further away from the target range. Management notes margin drag from US branded business.
Call transcript, Q1 FY27 · 4 Aug 2026		At Risk
ROW Business Growthbetween 12%, 15%, somewhere around there
Call transcript, Q4 FY25 · 6 May 2025		Q4 FY25Q4 FY26:Full year Ex-U.S. markets grew 20%, meeting the revised 15-20% target.
Call transcript, Q4 FY26 · 21 May 2026		Achieved

Source: Inve Guidance Tracker for Alembic Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Alembic Pharmaceuticals Limited's 19 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 16 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹766.9 +0.07% · +₹0.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −17.1% 1Y

₹700₹800₹900Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 4 Nov 2025Q3 FY26 — 5 Feb 2026Q4 FY26 — 21 May 2026Q1 FY27 — 4 Aug 2026

1Y: ₹924.6 on 24 Oct 2025 → ₹766.9. High ₹960.7 (4 Nov 2025), low ₹646.55 (23 Mar 2026).

Previous close
₹766.4
Market cap
₹15.1k Cr
52-week range
₹646.55 – ₹960.7
One year
−16.18%
Price to earnings (TTM to Jun 2026)
20.19×
Return on equity (TTM to Jun 2026)
13.73%

Overview

Symbol
NSE:APLLTD
Exchange
NSE
Currency
INR

What Alembic Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Alembic Pharmaceuticals, founded in 1907 and headquartered in Vadodara, Gujarat, is a research-driven integrated pharmaceutical company that develops, manufactures and markets branded generic formulations in India, generic and branded formulations in the US and other international markets, and Active Pharmaceutical Ingredients (APIs) sold to formulators worldwide. It operates through three business verticals - India Branded Business, International Generics (US and Rest-of-World), and API - run out of 10 manufacturing facilities and 2 R&D centres (Vadodara and Hyderabad). Its India business markets branded generics across therapies such as cardiology, gastrology, gynaecology, anti-infectives, cough & cold and animal health through a field force of medical representatives spread across marketing divisions nationwide, while its API business supplies active ingredients to customers in 60+ countries.

Segments

  • India Branded Business
  • US Formulation
  • Ex-US Formulation (International Generics)
  • API (Active Pharmaceutical Ingredients)
Manufacturing facilities
10
Cumulative ANDA filings with USFDA
274 filed, 235 approved (incl. 19 tentative)
R&D centres
2 (Vadodara and Hyderabad)
Generic products commercialised in the US
178
Field force (medical representatives)
5,500+ across 21 marketing divisions
Branded formulations (India)
208
Founded 1907Headquarters Vadodara, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
+0.5%
4 Aug
Q4 FY26
−0.5%
21 May
Q3 FY26
+1.5%
5 Feb
Q2 FY26
+3.9%
4 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Alembic Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Alembic Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Alembic Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.